Related Experiment Video
Updated: Sep 11, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes
Athena Philis-Tsimikas1, Jens Aberle2, Harpreet Bajaj3
1Scripps Whittier Diabetes Institute, 9834 Genesee Ave, Suite 300, La Jolla, CA, 92037, USA. tsimikas.athena@scrippshealth.org.
Drugs
|August 13, 2025
Summary
Insulin icodec, a once-weekly basal insulin, offers a new treatment option for type 2 diabetes. This review provides practical guidance for healthcare professionals on its real-world clinical use.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetes Management
Background:
- Insulin icodec is a novel, once-weekly basal insulin for type 1 and type 2 diabetes.
- Real-world implementation guidance is needed for healthcare professionals (HCPs).
Purpose of the Study:
- To provide evidence-based clinical recommendations and expert opinions for using insulin icodec in type 2 diabetes (T2D).
- To guide HCPs in translating icodec use from clinical trials to practice.
Main Methods:
- Review of available evidence for icodec in T2D.
- Summary of pharmacology and results from ONWARDS 1-6 clinical trials.
- Inclusion of expert opinions and practical usage guidance.
Main Results:
- Provides guidance on treatment initiation, switching regimens, and dose titration.
- Discusses icodec use in special populations and practical situations.
- Addresses glucose monitoring, management, and co-administration with other medications.
Conclusions:
- This review serves as a comprehensive resource for HCPs on the clinical application of insulin icodec in T2D.
- Offers practical insights for safe and effective implementation of once-weekly basal insulin therapy.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
374
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
374
01:16Insulin: Dosing Regimen and Adverse Effects
259
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
259
01:27Insulin Formulations: Types and Delivery
272
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
272
01:28Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
01:25Insulin: Biosynthesis, Chemistry, and Preparation
529
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
529
01:22Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K